Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective

Journal of Psychopharmacology

Volumn 29, Issue 1, 2015, Pages 43-49

  Nutt, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

buprenorphine; buprenorphine naloxone; harm reduction; heroin addiction; methadone; Opiate dependence; recovery

Indexed keywords

BUPRENORPHINE; METHADONE; NALMEFENE; NALOXONE; NALTREXONE; NARCOTIC AGENT;

ARTICLE; BEHAVIOR CHANGE; CLINICAL HANDOVER; COMMUNITY INTEGRATION; COMORBIDITY; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MISUSE; DRUG SAFETY; GOAL ATTAINMENT; HEALTH CARE PLANNING; HEROIN DEPENDENCE; HUMAN; PATIENT COMPLIANCE; PATIENT PARTICIPATION; REHABILITATION CARE; SOCIAL INTERACTION; UNITED KINGDOM; COMBINATION DRUG THERAPY; DRUG COMBINATION; GREAT BRITAIN; OPIATE SUBSTITUTION TREATMENT; PROCEDURES;

BUPRENORPHINE; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HEROIN DEPENDENCE; HUMANS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT;

EID: 84918495124     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114555248     Document Type: Article

References (77)

1. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007 ; 88 (1). 75-78
2. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend. 2001 ; 61 (2). 173-181
3. Bacha J, Reast S, Pearlstone A. Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl. 2010 ; 12 (3). 9-19
4. Bell J, Trinh L, Butler B, et al. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009 ; 104 (7). 1193-1200
5. BestDRomeAHanningKA. (2010) Research For Recovery: A Review of the Drugs Evidence Base. www.scotland.gov.uk. Available at: www.scotland.gov.uk/socialresearch (accessed 5 Sep 2013).
6. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985 ; 57 (2). 192-196
7. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. Med J Aust. 1999 ; 170 (3). 104-109
8. Center for Substance Abuse Treatment (2005) Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series, No. 43. http://www.ncbi.nlm.nih.gov/books/NBK64151/. Available at: http://www.ncbi.nlm.nih.gov/books/NBK64151/ (accessed 22 Aug 2012).
9. Chadderton A. Clinical issues in using buprenorphine in the treatment of opiate dependence. Drug Alcohol Rev. 2000 ; 19 (3). 329-335
10. Chen KW, Berger CC, Forde DP, et al. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry. 2011 ; 11: 90
11. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003 ; 70: S39 - S47
12. Corkery JM, Schifano F, Ghodse AH, et al. The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004 ; 19 (8). 565-576
13. Cowan A. Buprenorphine: New pharmacological aspects. Int J Clin Pract Suppl. 2003 ; (133). 3-8
14. CoxBMBorsodiACalóG. (2009) Opioid receptors, introductory chapter. http://www.iuphar-db.org 13-10-2009. Available at: http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=50 (accessed 3 Sep 2013).
15. Curcio F, Franco T, Topa M, et al. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. Eur Rev Med Pharmacol Sci. 2011 ; 15 (8). 871-874
16. Dale-Perera A, Goulão J, Stöver H. Quality of care provided to patients receiving opioid maintenance treatment in Europe: Results from the EQUATOR. Heroin Addict Relat Clin Probl. 2012 ; 14 (4). 23-38
17. Department of Health (England) and the devolved administrations (2007) Drug Misuse and Dependence: UK Guidelines on Clinical Management. www.nta.nhs.uk2007. Available at: www.nta.nhs.uk/publications (accessed 26 Oct 2012).
18. Doran C, Holmes J, Ladewig D, et al. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addict Relat Clin Probl. 2005 ; 7 (1). 7-18
19. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002 ; 41 (14). 1153-1193
20. Fareed A, Vayalapalli S, Casarella J, et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012 ; 31 (1). 8-18
21. Feltenstein MW, See RE. The neurocircuitry of addiction: An overview. Br J Pharmacol. 2008 ; 154 (2). 261-274
22. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2012 ; 126 (1). 74.e11-17
23. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999 ; 94 (9). 1337-1347
24. FordCHallidayKLawsonE. (2011) Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care. www.rcgp.org.uk and www.smmgp.org.uk. Available at: www.smmgp.org.uk/download/guidance/guidance004.pdf (accessed 5 Feb 2013).
25. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 ; 349 (10). 949-958
26. Giacomuzzi SM, Ertl M, Kemmler G, et al. Sublingual buprenorphine and methadone maintenance treatment: A three-year follow-up of quality of life assessment. ScientificWorldJournal. 2005 ; 5: 452-468
27. Giacomuzzi SM, Riemer Y, Ertl M, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: A health-related quality of life assessment. Addiction. 2003 ; 98 (5). 693-702
28. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2009 ; 3: CD002025
29. Gowing LR, Farrell M, Bornemann R, et al. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006 ; 21 (2). 193-195
30. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV /AIDS Rep. 2010 ; 7 (3). 152-160
31. Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000 ; 67 (5-6). 423-428
32. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000 ; 61 (1). 85-94
33. HM Government (2010) Drug strategy 2010: Reducing demand, restricting supply, building recovery: Supporting people to live a drug free life. www.homeoffice.gov.uk2010. Available at: www.homeoffice.gov.uk/drugs/drug-strategy-2010/ (accessed 15 Mar 2012).
34. Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000 ; 343 (18). 1290-1297
35. Kidorf M, King VL, Neufeld K, et al. Involving significant others in the care of opioid-dependent patients receiving methadone. J Subst Abuse Treat. 2005 ; 29 (1). 19-27
36. Kiser JJ, Burton JR, Anderson PL, et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 ; 55 (5). 1620-1628
37. Larance B, Degenhardt L, Lintzeris N, et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011 ; 118 (2-3). 265-273
38. Laudet AB, Becker JB, White WL. Don't wanna go through that madness no more: Quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Subst Use Misuse. 2009 ; 44 (2). 227-252
39. Law FD, Bailey JE, Allen DS, et al. The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. Addiction Biology. 1997 ; 2: 191-200
40. LeavittSB (2003) Methadone Dosing & Safety in the Treatment of Opioid Addiction. Addiction Treatment Forum. Available at: http://www.atforum.com/pdf/DosingandSafetyWP.pdf (accessed 19 Jun 2013).
41. Leonardi C, Hanna N, Laurenzi P, et al. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend. 2008 ; 94 (1-3). 125-132
42. Leshner AI. Addiction is a brain disease, and it matters. Science. 1997 ; 278 (5335). 45-47
43. LintzerisNClarkNWinstockA. (2006) National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence. www.health.gov.au. Available at: www.health.gov.au/internet/drugstrategy/publishing.nsf/Content/buprenorphine-guide (accessed 14 Feb 2011).
44. Lintzeris N, Rushmore L, Bammer G, et al. Randomised controlled trials of buprenorphine in the management of inpatient and outpatient heroin withdrawal. Research and Clinical Forums. 2001 ; 23 (1). 49-59
45. Maddux JF, Desmond DP. Ten-year follow-up after admission to methadone maintenance. Am J Drug Alcohol Abuse. 1992 ; 18 (3). 289-303
46. Magura S, Rosenblum A Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored MT SINAI J Pfizer MEDICINE 68 ; 2001: 62-74.
47. Mannelli P, Peindl KS, Lee T, et al. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: State of the art and new perspectives. Curr Drug Abuse Rev. 2012 ; 5 (1). 52-63
48. Mannelli P, Peindl KS, Wu LT. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Subst Abuse Rehabil. 2011 ; 2011 (2). 113-123
49. Maremmani I, Pacini M, Pani P. Basics on addiction: A training package for medical practitioners or psychiatrists who treat opioid dependence. Heroin Addict Relat Clin Probl. 2011 ; 13 (2). 5-40
50. Maremmani I, Pacini M, Lamanna F. Predictors for non-relapsing status in methadone-maintained heroin addicts. A long-term perspective study. Heroin Addict Relat Clin Probl. 2008 ; 10 (4). 19-28
51. Maremmani I, Pani PP, Pacini M, et al. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat. 2007 ; 33 (1). 91-98
52. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: The importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis. 2005 ; 41: S89 - S95
53. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?. Drug Alcohol Depend. 2003 ; 70: S29 - S37
54. National Treatment Agency for Substance Misuse (2006) Models of Care for Treatment of Adult Drug Misusers. http://www.nta.nhs.uk. Available at: http://www.nta.nhs.uk/uploads/nta-modelsofcare-update-2006-moc3.pdf (accessed 19 Jun 2013).
55. Nutt DJ. Addiction: Lifestyle choice or medical diagnosis?. J Eval Clin Pract. 2013 ; 19: 493-496
56. Nutt DJ. Antagonist-agonist combinations as therapies for heroin addiction: back to the future?. J Psychopharmacol. 2010 ; 24 (2). 141-145
57. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010 ; 106 (1). 56-60
58. Petitjean S, Stohler R, Deglon JJ, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001 ; 62 (1). 97-104
59. Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010 ; 39 (4). 340-352
60. Pirastu R, Fais R, Messina M, et al. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend. 2006 ; 83 (2). 163-168
61. Platt JJ. Vocational rehabilitation of drug abusers. Psychol Bull. 1995 ; 117 (3). 416-433
62. Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007 ; 33 (5). 631-642
63. Powers KI, Anglin MD. A differential assessment of the cumulative versus stabilizing effect of methadone maintenance treatment. Eval Rev. 1998 ; 22 (2). 175-206
64. Richardson L, Wood E, Montaner J, et al. Addiction treatment-related employment barriers: The impact of methadone maintenance. J Subst Abuse Treat. 2012 ; 43 (3). 276-284
65. SAMHSA (2009) Guiding Principles and Elements of Recovery-Oriented Systems of Care: What do we know from the research?www.samhsa.gov (accessed 2 Aug 2012).
66. Skinner ML, Haggerty KP, Fleming CB, et al. Opiate-addicted parents in methadone treatment: Long-term recovery, health, and family relationships. J Addict Dis. 2011 ; 30 (1). 17-26
67. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: A review. Drug Alcohol Depend. 2000 ; 59 (1). 17-31
68. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005 ; 20 (11). 1038-1041
69. Stine SM, Kosten TR. Use of drug combinations in treatment of opioid withdrawal. J Clin Psychopharmacol. 1992 ; 12 (3). 203-209
70. StrangJ (2012) Medications in recovery re-orientating drug dependence treatment. Accessed on 25 February 2012 from: www.nta.nhs.uk/medications-in-recovery-main-report.aspx.
71. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011 ; 106 (11). 1978-1988
72. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003 ; 70: S13 - S27
73. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994 ; 55 (5). 569-580
74. Wesson DR. Buprenorphine in the treatment of opiate dependence: Its pharmacology and social context of use in the U.S. J Psychoactive Drugs. 2004 ;: 119-128
75. WHO UNODC UNAIDS (2004) WHO/UNODC/UNAIDS position paper: Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. www.who.int. Available at: www.who.int/substance-abuse/publications/treatment/en/index.html (accessed 19 Jun 2013).
76. World Health Organization (2009) Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. www.who.int. Available at: www.who.int/substance-abuse/publications/treatment/en/index.html (accessed 19 Jun 2013).
77. Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction. 2000 ; 95 (1). 77-84